ROSEVILLE, Minn., Dec. 6,
2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT),
a plant-based synthetic biotechnology company, today announced the
hiring of two senior roles important to furthering Calyxt's
recently announced strategic direction. Joining the Company are
Vijay Gullapalli, Ph.D., as Vice
President, Artificial Intelligence/Machine Learning (AI/ML) and
Data Science, reporting to Travis
Frey, Ph.D., Chief Technology Officer; and Pete Ball as Technology Licensing Leader,
reporting to Debra Frimerman,
General Counsel and Corporate Secretary.
"I welcome Vijay and Pete to Calyxt as key hires to help drive
our strategy to deliver plant-based synthetic biology solutions to
important customers in our identified key end markets. We aim to
enable these customers to create target products from formerly
finite ingredients while delivering against their corporate
sustainability goals," said Michael A.
Carr, President and Chief Executive Officer at Calyxt.
"At Calyxt, we are using our PlantSpring™ technology
platform to create bespoke molecules from plants, for a variety of
end markets. PlantSpring relies on an iterative prototyping cycle
of design, engineer, verify and learn, aided by AI and machine
learning capabilities. Vijay's experience and expertise building
innovative AI-based solutions will be invaluable as we continue to
develop and augment those AI and machine learning capabilities
within PlantSpring," added Mr. Carr. "Further, Pete's addition to
the team will enable us to advance our licensing activities in both
our platform technologies, including IP relating to gene-editing in
plants, and our portfolio of crop innovations. We welcome Pete's
deep legal acumen and proven ability to build value through
partnering."
Dr. Gullapalli brings nearly 25 years of experience in
developing solutions for businesses across diverse industries
utilizing his expertise in data technology and AI/machine learning.
He joins Calyxt from Blue Cross Blue Shield of North Carolina, where he served as Vice
President of Analytics & Insights. Previously, he worked at
Capital One, serving as Director, Card Machine Learning and Data
Transformation and HSBC, as Vice President, Global Information
Management. Prior to these roles, Dr. Gullapalli served as Chief
Technology Officer at Hypertech Solutions. He holds a B.S. in
Electrical Engineering, an M.S. in Mathematics from Birla Institute
of Technology & Science, Pilani, India, and an M.S. and Ph.D. in Computer
Science, Machine Learning, from the University
of Massachusetts, Amherst.
Mr. Ball has nearly 35 years of legal and technology licensing
experience and joins Calyxt from North Shore Therapeutics, where he
served as Chief Executive Officer. Prior to North Shore, he served
as Chief Corporate Development Officer at ConsenSys Health.
Previously, Mr. Ball served as Senior Technology Licensing Manager
at Mayo Clinic Ventures, and as Portfolio Director, Technology
Licensing at Johns Hopkins Technology Ventures. In addition to his
experience in software development, Mr. Ball has a background in
operations management, having begun his career at United Parcel
Service. Mr. Ball holds a B.A. in Psychobiology from Hamilton College, an M.S. in Operations Research
from Columbia University, and a J.D.
from the University of Baltimore, School of
Law.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based
synthetic biotechnology company. The Company leverages its
proprietary PlantSpring™ technology platform to engineer innovative
materials and products for its customers to help them meet their
sustainability goals. Calyxt's diversified offerings are primarily
delivered through its proprietary BioFactory™ production system.
For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of
Calyxt, Inc. Any other trademarks belong to their respective
owners.
Contacts:
Calyxt Media
Contact:
|
Calyxt Investor
Relations Contact:
|
David Rosen/John
Garabo/Michael Barron
Argot
Partners
(212)
600-1902
media@calyxt.com
|
Sherri Spear/Cameron
Willis
Argot
Partners
(212)
600-1902
investors@calyxt.com
|
|
|
Calyxt Business
Development Contact:
|
|
Sarah
Reiter
Calyxt,
Inc.
(612)
427-7881
contact@calyxt.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calyxt-announces-strategic-hires-in-aiml-and-technology-licensing-301437514.html
SOURCE Calyxt, Inc.